The MCF-7 human breast cancer cell line responds to estrogen stimulation in vitro by increased secretion of growth factors and proliferation and in vivo by tumor formation in the nude mouse. To test a possible role of growth factor secretion in expression of the tumorigenic phenotype, we stably transfected MCF-7 cells with the v-Ha-ras oncogene to produce the MCF-7ras cell line. The MCF-7ras cell line was tumorigenic in the absence of estrogens and secreted 3-to 5-fold elevated levels of a high molecular weight form of a type a transforming growth factor-like growth factor, type ,B transforming growth factor, and insulin-like growth factor I. MCF-7ras cells, in contrast to MCF-7, were less sensitive to further growth stimulation by estrogen, type a transforming growth factor, and insulin-like growth factor I and showed little change in receptor levels for these hormones. Conditioned medium from MCF-7ras cells as well as two of its component growth factors (insulin-like growth factor I and type a transforming growth factor) replaced estrogen in stimulating MCF-7 colony formation in vitro. A coordinate increase in growth factor secretion by human breast cancer may contribute to its escape from estrogen dependence.
Human breast cancers are heterogeneous in their expression of receptors and responsiveness to 173-estradiol. Clinically, human breast cancer may often be 17p3-estradiol-responsive initially, but later may progress to a more aggressive, hormone-independent form (1) . Both hormone-responsive and hormone-independent tumor types may be studied in vitro using a variety of human breast cancer cell lines of both phenotypes (2) .
The MCF-7 cell line, originally derived from the pleural metastases of a patient with adenocarcinoma ofthe breast (2), contains specific 17,B-estradiol receptors and exhibits obligate 17p-estradiol-dependence for tumor formation in the athymic (nude) mouse (3) . MCF-7 cells and other estrogen receptor-containing cell lines respond to 1703-estradiol treatment in vitro with an increased growth rate and with secretion of growth factor activities (4), including a 30-kDa peptide whose activity resembles type a transforming growth factor (TGF-a) (5) (6) (7) . Type /3 transforming growth factor (TGF-f3), insulin-like growth factor I, and a platelet-derived growth factor (PDGF)-related polypeptide are also secreted. The fact that epidermal growth factor (EGF) and IGF-I are growth promoting for MCF-7 and some other human breast cancer cell lines (8) (9) (10) has led us to believe that TGF-a and IGF-I might be autocrine growth factors. TGF-,B, found in platelets and usually secreted by cultured cells in inactive form, is growth inhibitory for receptor-containing breast cancer cell lines (11, 12, 41) while PDGF is not known to be mitogenic for breast cancer. PDGF and TGF-f3 may stimulate stromal proliferation around the tumor in vivo, acting as supportive, paracrine hormones (13) .
In an effort to understand more fully the events leading to enhanced growth factor production and tumorigenesis, we have established and described a clone of MCF-7 cells, MCF-7ras, stably transfected by the v-Ha-ras oncogene in the presence of a selectable bacterial gene marker Ecogpt (14) . We also prepared a control transfectant line MCF-7gpt containing only the selectable marker. This latter cell line was quite similar to wild-type MCF-7 in those phenotypic markers examined (growth rate, its 17f-estradiol responsivity in vitro and in vivo, major intracellular and secreted proteins, responsiveness to antiestrogens, and presence of receptors for estrogen, EGF, and IGF-I). The MCF-7ras cell line retained the ability to respond to 17p-estradiol exposure as measured by induction of progesterone receptor, but had severely blunted growth responses to 17,3-estradiol and antiestrogen in vitro. In addition the cell line had become estrogen-independent for tumorigenicity in vivo. Because we had shown that 17/3-estradiol stimulation of MCF-7 cells was required for tumorigenicity in vivo and was accompanied by enhanced growth factor secretion (6, 7), we examined whether the MCF-7ras cells secreted activated growth factor in conjunction with their autonomous tumorigenic capacity and whether this growth factor secretion was responsible for tumor growth.
EXPERIMENTAL METHODS Cell Culture. MCF-7 cells (2) were originally obtained from Marvin Rich, Michigan Cancer Foundation, Detroit, MI. Cells were cultured in 10% (vol/vol) fetal calf serum or in 5% (vol/vol) sulfatase and charcoal-treated calf serum in phenol red-containing improved minimum essential medium (IMEM) (GIBCO) as described (6, 7) . A late passage (200) clone of MCF-7 cells stably cotransfected with the transforming DNA from Harvey murine sarcoma virus and the selectable marker pSV2gpt were also used (MCF-7ras) (14) . A paired control line transfected only with pSV2gpt (MCF7gpt) was used as a control for all MCF-7ras studies. For 17p3-estradiol-treatment studies, wild-type MCF-7 cells were treated with 1 nM 17f3-estradiol or the ethanol vehicle for 4 days (6, 7). DNA was routinely assayed in cell sonicates by a fluorometric assay (15) . The 48-hr conditioned medium (CM) collections were carried out, and CM was concentrated and extracted with acid as described (7) . Anchorage-independent growth of rat NRK cells, a "transforming growth" assay was carried out as described by Delarco et al. (16) . CM from Moloney murine sarcoma virus-transformed 3T3 cells (MoMSV-3T3) (from American Type Culture Collection) was routinely used as a positive control.
Growth Factor Assays. The transforming growth assay (16) used was sensitized for the detection of TGF-a-like activity.
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Serum containing a high level of TGF-f3 activity was used. TGF-a-like activity was assayed using 125I-labeled EGF (from mouse, Bethesda Research Laboratories) (17) , and the competitive, specific radioreceptor assay (A431 carcinoma cells) of Delarco et al. (16) . TGF-,p was also assayed by a competitive, specific radioreceptor assay (18) (20) was carried out to screen for PDGF activity. NIH 3T3 cells were used in an assay as described (20) using [14C]thymidine (0.5 ,tCi/ml, New England Nuclear). Fibroblast growth factor (200 ng/ml, 80% purified factor; Bethesda Research Laboratories) and PDGF (200 ng/ml, 50,000 units/mg; Biomedical Technologies, Norwood, MA) were used as positive controls. For these experiments CM was generally prepared by culturing cells in 0.5% platelet-poor plasma and then concentrating 10-fold by Amicon filtration (see above). CM from NIH 3T3 cells was used as a negative control, and CM from simian sarcoma virus-transformed 3T3 (SSV-3T3) cells (a gift from Mark Israel, National Institutes of Health) and MoMSV-3T3 cells were positive controls. Growth factor measurements were sometimes normalized for DNA content of producer cell monolayer or for bulk secreted protein (dpm of [3H]leucine) (6) . Sometimes ratios were taken between 17,8-estradiol-or v-Ha-ras-stimulated values and appropriate controls. Data are always representative of at least three independent experiments.
Receptor Measurements. EGF receptor was determined using human EGF (Amgen) iodinated by chloramine-T (17) . Binding assays and Scatchard analysis were carried out as described (21) . IGF-I receptor was determined using human IGF-I (Amgen) iodinated by chloramine-T (16). Binding assays and Scatchard analysis were carried out as described (9) . TGF-,B receptor was determined using human plateletderived TGF-p. Binding assays were carried out as described (19) .
Colony Stimulation Assays for Growth Factor Activities. To determine if v-Ha-ras transfection of MCF-7 cells resulted in enhancement of diffusible mitogenic activities, a coculture procedure was developed. Four compartment, 100-mm diameter culture dishes (Falcon x-plate #1009) were coated with poly(D-lysine) (Sigma) prior to use (22 (Table 2) . MCF-7ras CM was fractionated by gel exclusion chromatography (Fig. 2) . Assay of column fractions for EGF-receptor binding activity and NRK transforming activity identified a peak containing a 30-kDa material, which was similar to that obtained with CM from 173-estradiol-stimulated MCF-7 cells (6, 7). Acid Bio-Gel P-150 chromatography of CM from 17/3-estradiol-treated MCF-7 and from MCF-7ras cells also identified the 30-kDa material.
TGF-f3. TGF-P3, which complements TGF-a in transformation of fibroblasts, was quantitated by a specific radioreceptor assay (19) . TGF-,B was elevated 5-fold in MCF-7ras cells compared with the MCF-7gpt control cells (Table 2) , a concentration reported to affect fibroblast growth (19) . Acid Bio-Gel P-60 fractionation of MCF-7ras CM showed that a polypeptide detected by TGF-P3 radioreceptor assay comi- IGF-I. IGF-I has been shown (25) to be required for full expression of the transformed phenotype. IGF-I was assayed by radioimmunoassay in MCF-7 CM using a specific antiserum and authentic IGF-I (Table 2) TGF-a-like activity) . Acid-dialyzed 330 x CM concentrate (3 ml) was applied to a Bio-Gel P-60 column (300 ml, bed volume). Fractions (170 drop) were diluted with 1 M acetic acid directly assayed for A280. After lyophilization of fractions and reconstitution with Dulbecco's PBS, pH 7.2 (GIBCO), NRK transforming activity and TGF-a were determined. Molecular size standards are as follows: 29-kDa carbonic anhydrase; 13.8-kDa ribonuclease A; 6-kDa insulin. CM samples were not precisely normalized for producer cell number here; quantitative comparisons between MCF-7gpt and MCR-7ras are in Tables 1 and 2. TGF-P, and IGF-I to support the maximal expression of transformation of fibroblasts (26) . In contrast to TGF-a, TGF-f3, and IGF-I, PDGF activity was not further elevated in MCF-7ras cells or in MCF-7 cells stimulated by 17f3-estradiol under these conditions (Table 3) .
Receptor Levels and Growth Factor Sensitivity. Secretion of three growth factors was elevated by v-Ha-ras oncogene transfection into MCF-7 cells in association with development of estrogen and antiestrogen autonomy of the cells (14) . MCF-7ras retained substantial amounts of the estrogen receptor (14) . In addition, EGF and IGF-I receptors (initially low, but functional) were not significantly down-modulated in MCF-7ras cells (Table 4 ). The TGF-f3 receptor was undetectable (less than 500 sites per cell) in the high-affinity (10 pM Kd) range on both MCF-7gpt and MCF-7ras cells.
Other clones of MCF-7 cells that contain the 8 receptor and that are growth inhibited by TGF-,B have been described (11, 41) , but in the current study the late passage MCF-7ras and MCF-7gpt clones did not have detectable TGF-,3 receptors and did not manifest a growth response to TGF-,B. As expected, the MCF-7ras cells showed little stimulation of colony formation by 17p-estradiol when compared to MCF7gpt cells (data not shown). Fig. 3 shows that the growth of MCF-7gpt cells, in contrast to MCF-7ras cells, was stimulated by both TGF-a and EGF. The growth of MCF-7gpt cells, also in contrast to MCF-7ras cells, was stimulated by IGF-I. The concentration of IGF-I that gave the maximal number ofcolonies was 1 ng/ml; 0.2 ng/ml was half-maximal.
DISCUSSION
Estrogen stimulation and v-Ha-ras transfection are independent tumorigenic stimuli for the MCF-7 breast cancer cell line. The tumorigenic signal(s) provided by either of these stimuli are accompanied by the augmented production of growth factors that accumulate to physiologically relevant concentrations. In addition, several tumorigenic, estrogen receptor-negative breast cancer cell lines have been reported that constitutively secrete high levels of TGF-a, TGF-,/, and IGF-I (5) (6) (7) (8) . The data reported here for breast cancer coupled with the findings of others (16, (27) (28) (29) (30) (31) (32) provide strong circumstantial evidence that some growth factors are closely associated with the tumorigenic phenotype as achieved by a variety of means. Furthermore, they suggest that enhanced secretion of growth factors may also play a role in a late step in escape of a breast tumor from the requirement for estrogen. In addition, the CM cross-feeding experiment (29) (30) (31) (32) . TGF-a, TGF-P, IGF-I, and PDGF activities are all required for full manifestation of the transformed, anchorage-independent phenotype in nontransformed murine fibroblasts (16, 25, (29) (30) (31) (32) . In contrast to the fibroblast system, the growth of MCF-7 breast carcinoma cells is only stimulated in vitro by IGF-I and TGF-a. TGF-/3 has been shown to be a hormonally regulated, negative-growth modulator for receptor-containing breast cancer cells (41 (25) , their production by human cancer has been documented so far for only breast cancer and fibrosarcoma (6, 7, (36) (37) (38) . Interestingly, the MCF-7ras cells bypassed the effects of exogenous EGF, TGF-a, and IGF-I in conjunction with increased growth factor production but without substantial receptor down-regulation. In summary, we have provided evidence for commonality in the mechanisms of MCF-7 tumorigenesis triggered by hormonal and oncogene signals. Growth factor secretion as triggered by either stimulus could be important in either autocrine or paracrine (i.e., growth or chemotactic effects on the tumor blood vessel supply or connective tissue) modes (39, 40) . In addition, induced growth factors could act in conjunction with other tumor products, such as proteases (33) , in the promotion of tumor growth.
